<?xml version="1.0" encoding="UTF-8"?>
<ref id="B102-viruses-12-00518">
 <label>102.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kim</surname>
    <given-names>K.H.</given-names>
   </name>
   <name>
    <surname>Kwon</surname>
    <given-names>Y.M.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>Y.T.</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>M.C.</given-names>
   </name>
   <name>
    <surname>Hwang</surname>
    <given-names>H.S.</given-names>
   </name>
   <name>
    <surname>Ko</surname>
    <given-names>E.J.</given-names>
   </name>
   <name>
    <surname>Lee</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Choi</surname>
    <given-names>H.J.</given-names>
   </name>
   <name>
    <surname>Kang</surname>
    <given-names>S.M.</given-names>
   </name>
  </person-group>
  <article-title>Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus</article-title>
  <source>Vaccines</source>
  <year>2018</year>
  <volume>6</volume>
  <elocation-id>66</elocation-id>
  <pub-id pub-id-type="doi">10.3390/vaccines6040066</pub-id>
 </element-citation>
</ref>
